Ontology highlight
ABSTRACT:
SUBMITTER: Hoshide S
PROVIDER: S-EPMC8029901 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Hoshide Satoshi S Kabutoya Tomoyuki T Ueno Hiromi H Kario Kazuomi K
Journal of clinical hypertension (Greenwich, Conn.) 20191224 3
A direct comparison of the effects of febuxostat and allopurinol on flow-mediated dilatation (FMD) will help to clarify which agent provides a better reduction of cardiovascular risk in hypertensive patients. Hypertensive patients with hyperuricemia were randomized into a febuxostat (10-40 mg, n = 33) or allopurinol (100-200 mg, n = 31) group and followed up for 6 months. Both the febuxostat (7.9 ± 1.3 mg/dL vs 5.6 ± 1.0 mg/dL, P < .001) and allopurinol (8.2 ± 1.3 mg/dL vs 6.1 ± 1.0 mg/dL, P < . ...[more]